Telaprevir in Null-Responders & NonResponders, rollover Study 107 - see attached full slide report

Telaprevir in Null-Responders & NonResponders, rollover Study 107 - see attached full slide report


Reported by Jules Levin
EASL 2010 Vienna April 14-18, Austria

There were severa interesting oral presentations today, the first day of the European Liver Conference, EASL, where it has become the favorite place for companies to present new data on the new oral HCV drugs in development. This was a small rollover study where patients who were non-responders from earlier studies of telaprevir who received peg/rbv only in those previous studies now received telaprevir+p eg/RBV in this rollover study.

Overall, the SVR rate was 59%: 37% in prior null responders, 55% in prior partial responders, 75% in prior breakthroughs, 97% in prior relapsers. See the tables in the attached report, of note 56% (15/27) prior null responders achieved SVR with 48 weeks therapy: T12/PR48, but only 17% (4/24) with 24 weeks total therapy- T12/PR24. For null-responder patients who achieved undetectable at week 4 57% achieved SVR: 63% (10/16) who had a total 48 week peg/rbv & telaprevir for 12 weeks. A large phase 3 study is ongoing in null and partial responders as well as in relapsers.